

THE IMPACT OF AN INTEGRATED COACHING
PROGRAM FOR SURVIVORS OF ACUTE CORONARY
SYNDROMES ON THEIR CARDIOVASCULAR RISK
PROFILE

THESIS

Submitted for Partial Fulfillment of MD Degree in Cardiology

By

Amr Ibrahim Abd-El Aal

M.Sc Cardiovascular Medicine

Supervisors

Dr. Hussein Rizk, MD

**Prof. of Cardiology
Cairo University**

Dr. Soliman Gharib, MD

**Prof. of Cardiology
Cairo University**

Dr. Mohamed Mahmoud Abd-El Ghany, MD Prof. of Cardiology

Cairo University

Faculty of Medicine

Cairo University

2010

Abstract

Objective:

This study was conducted to determine the effect of an integrated cardiac rehabilitation program on the traditional cardiovascular risk factors in Egyptian and Saudi patients.

Material & Methods:

The study registered 41 Egyptian patients and 35 Saudi patients with known CAD who were enrolled in 12 months duration lifestyle intervention program during which they were instructed and encouraged to follow healthy lifestyle changes (Smoking cessation, regular physical activity, healthy diet, compliance to treatment and weight loss). Assessable risk factors parameters (Blood pressure, body mass index, and smoking, LDL, HDL and HbA1C) were obtained at end of the study and compared to that obtained at entry to determine the efficacy of the intervention program.

Results:

The intervention program was associated with significant reduction in T.chol. (188.71mg/dl vs. 174 mg/dl, $p=0.05$), LDL (119.07 mg/dl vs. 100.05 mg/dl, $p=0.021$) and DBP (78.7 mmHg vs. 74.6 mmHg, $p=0.03$) in Egyptian patients. Also, the Saudi patients showed significant reduction in T.chol. (190.4 mg/dl vs. 173 mg/dl, $p=0.02$), LDL (121.2 mg/dl vs. 108.3 mg/dl, $p=0.04$) and HbA1C (8.7 vs. 8 , $p=0.005$) at the end of the program. There was no statistically significant difference between Egyptian and Saudi Patients regarding final parameters and final Framingham risk score.

Conclusion:

This study demonstrated that cardiac rehabilitation program is associated with significant improvement of cardiac risk factors specifically T. Chol., LDL-C , DBP and HBA1C. Both the Egyptian and Saudi patients show significant improvement in their cardiac risk factors and Framingham risk score.

Keywords: Cardiac rehabilitation, Coronary artery disease

CONTENTS

	Page
List of abbreviations	I
List of tables	III
List of figures	V
INTRODUCTION AND OBJECTIVE OF THE STUDY	1
REVIEW OF LITERATURE	
Chapter (1) : Epidemiology of Cardiovascular Disease	4
Chapter (2) : Biology of Atherosclerosis	13
Chapter (3) : Cardiac Rehabilitation and Secondary Prevention	23
Chapter (4) : Exercise & Physical Activity	42
Chapter (5) : Nutrition & Cardiovascular Disease	58
Chapter (6) : Smoking	79
PATEINTS AND METHODS	91
RESULTS	
Section [A]: Baseline data, final data, targets reached and independent predictors for achieving these targets of the whole study population	101
Section [B]: Baseline data, final data, targets reached and independent predictors for achieving these targets of the the Egyptian patients	116
Section [C]: Baseline data, final data, targets reached and independent predictors for achieving these targets of Saudi patients.	134
Section [D]: Comparison between the Egyptian and Saudi patients.	151
DISCUSSION	154
SUMMARY	169
REFERENCES	175

MASTER TABLE
ARABIC SUMMARY

LIST OF ABBREVIATIONS

1-RM	: Repeatiton maximim
ACS	: Acute Coronary Syndromes
BP	: Blood Pressure
BW	: Body Weight .
CAD	: Coronary Artery Disease
CHD	: Coronary Heart Disease.
CI	: Confidence Interval
CR	: Cardiac Rehabilatation
CVD	: Cardiovascular Diasease.
DBP	: Diastolic Blood Pressure
Dev E	: Developing Economies.
DHA	: Docosahexanoic Acid
DM	: Diabetes Mellitus.
DRR	: Death Rate Ratio
Em ME	: Emerging Market Economies. .
EPA	: Eicosapentanoic Acid
Est ME	: Established Market Economies.
GI	: Glycemic Index
HbA1C	: Glycated Haemoglobin
HDL-C	: High Density Lipoprotein -Cholesterol
HM G-CoA	: 3-hydroxy-3-methylglutaryl-coenzyme A
HRV	: Heart Rate Variability
hsCRP	: High sensitivity C-Reactive protein
HTN	: Hypertension.
ICAM -1	: Intercellular Adhesion Molecule-1
IHD	: Ishemic Heart Disease
Kcal	: Kilo Calories.
LDL	: Low Density Lipoprotein
LDL-C	: Low Density Lipoprotein-Cholesterol.
MAP	: Mean Arterial Pressure
MCP-1	: Monocyte Chemoattractant Protein-1.
METs	: Metabolic Equivelant
MI	: Myocardial Infarction.
MUFA	: Mono-Unsaturated Fatty Acids

NCEP	: National Cholesterol Education Program.
NNT	: Number Needed to Treat.
NO	: Nitric Oxide.
NRT	: Nicotine Replacement Therapy
NSTEMI	: Non-ST Elevation Myocardial Infarcion
OR	: Odd Ratio
PCI	: Percutaneous coronary intervention
PTCA	: Percutaneous transluminal coronary angioplasty.
PUFA	: Poly-Unsaturated Fatty Acids
QALY	: Quality-Adjust life-Year.
RR	: Relative Risk
SBP	: Systolic Blood Pressure
SHS	: Secondhand Smoke
STEMI	: ST Elevation Myocardial Infarcion
TC	: Total Cholesterol.
TG	: Triglyceride.
VCAM -1	: Vascular Cell Adhesion Molecule-1
VLDL-C	: Very Low Density Lipoprotein-Cholesterol
Vo2 max	: Maximal oxygen uptake
VSMCs	: Vascular Smoot Muscle Cells

LIST OF TABLES

Table no.		Page
Table 1	: Burden of diseases for the three economic regions of the world	5
Table 2	: Four typical stages of the epidemiological transition	6
Table 3	: Mortality by disease category in the developing world	9
Table 4	: Traditional terminology for the phases of cardiac rehabilitation	24
Table 5	: Components of cardiac rehabilitation and associated goals	26
Table 6	: Comparative cost effectiveness of treatments for coronary artery disease	40
Table 7	: Principles of exercise prescription	53
Table 8	: Classification of physical activity intensity	55
Table 9	: Various dietary patterns	62
Table 10	: Comparison of low-carbohydrate and reduced-fat diets	77
Table 11	: Responses of the cardiovascular system to secondhand smoking.....	81
Table 12	: Incremental effects of smoking cessation interventions on abstinence for 6 months or longer	87
Table 13	: Social score calculation method	95
Table 14	: NCEP Diet Components Recommendation.....	96
Table 15	: Adherence score	100
Table 16	: Baseline characteristics of whole study population: clinical, laboratory and examination data	102
Table 17	: Final parameters vs. Baseline parameters of whole study population.....	103
Table 18	: Characteristic features of who reached target BP vs. who did not reach target BP in whole study population.....	108
Table 19	: Characteristic features of patients who reached target LDL vs.who did not reach target LDL in whole study population.	110

Table 20	: Characteristic features of patients who reached target HDL vs. who did not reach target HDL in whole study population	112
Table 21	: Characteristic features of patients who reached target HbA1C vs. who did not reach target HbA1C in whole study population	113
Table 22	: Characteristic features of Non-smokers vs. smokers in whole study population.....	115
Table 23	: Baseline characteristics of Egyptian patients: clinical, laboratory and examination.....	117
Table 24	: Final parameters vs. baseline parameters in Egyptian patients	118
Table 25	: Characteristic features of patients who reached target BP vs. who did not reach target BP in Egyptian patients.	123
Table 26	: Characteristic features of patients who reached target LDL vs. who did not reach target LDL in Egyptian patients.	126
Table 27	: Characteristic features of patients who reached target HDL vs. who did not reach target HDL in Egyptian patients.	129
Table 28	: Characteristic features of patients who reached target HbA1C vs. who did not reach target HbA1C in Egyptian patients.	131
Table 29	: Characteristic features of non smokers vs. smokers in Egyptian patients	133
Table 30	: Baseline characteristics of Saudi patients: clinical, laboratory and examination data	135
Table 31	: Final parameters vs. baseline parameters in Saudi patients	136
Table 32	: Characteristic features of patients who reached target BP vs, who did not reach target BP in Saudi patients	140
Table 33	: Characteristic features of patients who reached target LDL vs. who did not reach target LDL in Saudi patients.	144
Table 34	: Characteristic features of patients who reached target HDL vs. who did not reach target HDL in Saudi patients.	146
Table 35	: Characteristic features of patients who reached target HbA1C vs. who did not reach target HbA1C in Saudi patients.	148
Table 36	: Characteristic features of non smokers vs. smokers in Saudi patients	150
Table 37	: Baseline characteristics of Egyptian vs. Saudi patients: clinical, laboratory and examination data	151
Table 38	: Final parameters in Egyptian vs. Saudi patients	152
Table 39	: % population that reached preset targets in Egyptian vs. Saudi patients	153

LIST OF FIGURES

Figure no.		Page
Figure 1	: Diagrammatic outline of the modern cardiac rehabilitation program	28
Figure 2	: Follow-up outline	98
Figure 3	: Baseline T.Cholesterol vs. Final T. cholesterol in whole study population.....	104
Figure 4	: Baseline LDL vs. Final LDL in whole study population	104
Figure 5	: Baseline HbA1C vs. Final HbA1C in whole study population	105
Figure 6	: Baseline DBP vs. Final DBP in whole study population	105
Figure 7	: Baseline risk score vs. Final risk score of whole study population	106
Figure 8	: % of whole study population with improved final risk score vs. not improved.....	106
Figure 9	: % of whole study population who reached target BP vs. who did not reach target BP	108
Figure 10	: Final risk score in whole study population who reached target BP vs. who did not reach target BP	109
Figure 11	: Final risk score in in whole study population who reached target LDL vs. who did not reach target LDL	111
Figure 12	: % of population who reached target HDL vs. who did not reach target HDL	111
Figure 13	: % non smokers vs. smokers of whole study population	114
Figure 14	: Baseline T.Cholesterol vs. final T. cholesterol in Egyptian patients.....	119
Figure 15	: Baseline LDL vs. final LDL in Egyptian patients	119
Figure 16	: Baseline DBP vs. Final DBP in Egyptian patients	120
Figure 17	: Baseline risk score vs. final risk score in Egyptian patients ...	120
Figure 18	: % of Egyptian patients with improved final risk score vs. not improved	121
Figure 19	: Adherence score of Egyptian patients with improved final risk score vs. not improved final risk score	121
Figure 20	: % of Egyptian patients who reached target BP vs. who did not reach target BP.....	122
Figure 21	: Body weight in Egyptian patients who reached target BP vs. who did not reach target BP.....	124

Figure 22	: Compliance to anti hypertensive drugs in Egyptian patients who reached target BP vs. who did not reach target BP.....	124
Figure 23	: Final risk score in Egyptian patients who reached target BP vs. who did not reach target BP.....	125
Figure 24	: % of Egyptian patients who reached target LDL vs. who did not reach target LDL	125
Figure 25	: Compliance to statin therapy in Egyptian patients who reached target LDL vs. who did not reach target LDL.....	127
Figure 26	: Social score in Egyptian patients who reached target LDL vs. who did not reach target LDL.....	127
Figure 27	: % of Egyptian patients who reached target HDL vs. who did not reach target HDL.....	128
 Figure 28	 : Body weight in Egyptian patients who reached target HDL vs. who did not reach target HDL.....	 130
Figure 29	: Social score in Egyptian patients who reached target HbA1C vs. who did not reach target HbA1C	132
Figure 30	: % non smokers vs. smokers in Egyptian patients	132
Figure 31	: Baseline T.Cholesterol vs. final T. cholesterol in Saudi patients	137
Figure 32	: Baseline LDL vs. final LDL in Saudi patients	137
Figure 33	: Baseline HbA1C vs. final HbA1C in Saudi patients	138
Figure 34	: Baseline risk score vs. Final risk score in Saudi patients	138
Figure 35	: % of Saudi patients with improved final risk score vs. not improved.....	139
Figure 36	: % of Saudi patients who reached target BP vs. who did not reach target BP	140
Figure 37	: Compliance to physical activity in Saudi patients who reached target BP vs. who did not reach target BP	141
Figure 38	: Aherence score in Saudi patients who reached target BP vs. who did not reach target BP	142
Figure 39	: Social score in Saudi patients who reached target BP vs. who did not reach target BP	142
Figure 40	: BMI in Saudi patients who reached target BP vs. who did not reach target BP	143
Figure 41	: Final risk score in Saudi patients who reached target BP vs. who did not reach target BP	143
Figure 42	: % Saudi patients who reached target HDL vs.who did not reach target HDL.....	145

Figure 43	: Social score in Saudi patients who reached target HDL vs. who did not reach target HDL	147
Figure 44	: Compliance to diet in Saudi patients who reached target HbA1C vs. who did not reach target HbA1C.....	149
Figure 45	: % non smokers vs. smokers in Saudi patients.....	149

INTRODUCTION

Coronary Artery Disease (CAD) is the most important public health problem in developed societies. Although the cardiovascular mortality rate has declined in recent decades, CAD remains the leading cause of death in these societies (1). CAD is also a major cause of physical disability, particularly in the rapidly growing population of elderly (2). Maintenance of physical functioning in patients with CAD and prevention of subsequent cardiac events are major challenges in recent medicine.

Cardiac rehabilitation programs were first developed in the 1960s, once the benefits of ambulation during prolonged hospitalization for coronary events had been recognized (3). Cardiac rehabilitation can be defined as (The sum of activity required to ensure cardiac patients the best possible physical, mental and social conditions so that they may by their own efforts regain as normal as possible a place in community and lead an active life). Major objectives of cardiac rehabilitation include not only an improved functional capacity and quality of life but also a reduction in mortality and morbidity (4).

American Heart Association (AHA) has stated that (compelling scientific evidence, including data from recent studies in patients with CAD demonstrated that comprehensive cardiac rehabilitation and secondary prevention including risk factor interventions extend overall survival, improve the quality of life, decrease the need for interventional

procedures such as angioplasty and bypass grafting and reduce the incidence of subsequent cardiac events).(5,6). **Both genders benefit (7).** However, evidence from all over the world has shown that cardiac rehabilitation and secondary prevention are only being partially applied in the clinical practice (8).This may be the result of decreased referral of patients to cardiac rehabilitation ,possibly because some clinicians consider that the overall benefits are not worth the costs and the patients efforts (4).

The impact of life style (diet counseling, body weight management, smoking cessation efforts and physical activity programs) modification on the cardiovascular risk status of survivors of acute coronary syndromes have been previously reported (9) but not in third world countries. The western instruments of intervention to modify risk factors and increase physical activity have not been tested in developing societies, where low socioeconomic status and a higher level of stress created by poverty & job insecurity among other environmental factors may limit the response to these interventions

OBJECTIVE OF THE STUDY

To develop and study the impact of an integrated cardiac rehabilitation program targeting the main measurable parameters of cardiovascular risk factors in Egyptian and Saudi patients presenting with acute coronary syndromes (unstable angina, myocardial Infarction) and/or underwent coronary revascularization.

CHAPTER 1

Epidemiology of Cardiovascular Disease

Over the past two centuries, the industrial, technological revolutions and their associated economic and social transformations have resulted in dramatic shifts in the diseases responsible for illness and death (10). Before 1900, infectious diseases and malnutrition were the most common causes of death. Chiefly, in developed countries and spreading to developing countries, this has gradually been replaced by chronic diseases as cancer and cardiovascular diseases (CVD), attributed largely to improved nutrition and public health.

CVD has emerged as the dominant chronic disease in many parts of the world. At the beginning of the 20th century, CVD accounted for less than 10% of all deaths worldwide. At the beginning of the 21st century, CVD accounted for nearly half of all deaths in the developed world and 25% in developing world (11). By 2020, it is predicted that CVD will claim 25 million lives annually and that coronary heart disease (CHD) will surpass infectious disease as the world's number one cause of death and disability (10).

The Epidemiological Transitions:

Epidemiological transitions are acknowledged as the shift in the diseases that account for the lion's share of mortality and morbidity. The epidemiological transition takes place at different rates around the world as it is tightly related to changes in personal and collective wealth (economic

transition), social structure (social transition) and demographics (demographic transition) (12).

According to the social and economic forces , the world is divided into three broad economic and geographical sectors with vast differences in diseases burden across these sectors (10) (Table 1) :

- 1- **The Established Market Economies (EstME):** Western Europe, North America, Australia , New Zealand and Japan.
- 2- **The Emerging Market Economies (EmgME):** Former socialist states of Eastern Europe.
- 3- **The Developing Economies (DevE):** which is subdivided into six geographical regions (China, India, other Asian countries, sub-Saharan africa, Middle Eastern Crescent and Latin America and the Carribbean).

	Population (Millions) (% of Total World Population)		Cardiovascular Disease (%)		Other Noncommu cable Diseases (%)		Communicable Maternal, Perinatal and Nutritional Conditions(%)		Injuries (%)	
	1990	2010	1990	2010	1990	2020	1990	2020	1990	2020
EstME	798 (15.2)	874 (14.6)	44.6	43.1	42.8	45.1	6.4	6.2	6.2	5.5
EmgME	346 (6.6)	363 (5.2)	54.6	55	29.5	32.2	5.6	3.5	10.3	8.8
DevE	4124 (78.3)	5764 (82.3)	23	31	17	31.2	41.9	24.7	10.7	12